Accentia Biopharmaceuticals Inc (1310094) SEC Filing 8-K Material Event for the period ending Monday, March 4, 2013

Accentia Biopharmaceuticals Inc

CIK: 1310094

View differences made from one to another to evaluate Accentia Biopharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Accentia Biopharmaceuticals Inc.


Assess how Accentia Biopharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Accentia Biopharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 1310094
Form Type: 8-K Corporate News
Accession Number: 0001214659-13-001282
Submitted to the SEC: Thu Mar 07 2013 4:56:54 PM EST
Accepted by the SEC: Thu Mar 07 2013
Period: Monday, March 4, 2013
Industry: Pharmaceutical Preparations
  1. Event for Officers
  2. Other Events

External Resources:

Bookmark the Permalink: